Posted 11 November 2020
Kynetyka Technologies Pty Ltd (“Kynetyka”), a privately held Melbourne-based medical device company led by Craig Newton and Xenia Sango, is delighted to announce that it has secured the support of Victoria’s Medical Device Partnering Program (MDPP) to further the development and clinical testing of Kynetyka’s DVTect™ technology for deep vein thrombosis (DVT) detection.
The support package includes the technical refinement of the DVTect™ hardware and software by research engineers at one of MDPP’s key partner organisations, Swinburne University, followed by a proof-of-concept clinical study in patients with DVT.
Kynetyka’s Director Xenia Sango said “We are delighted to receive this support from MDPP and to be working with Swinburne University. Their product design and engineering capability is world-class. Swinburne’s expertise will assist Kynetyka in our quest to develop a unique medical device that will enable the rapid and early screening of DVTs, potentially helping to save lives lost to pulmonary embolism.”
The proprietary DVTect™ device is designed to detect abnormalities of the calf muscle as a predictor of DVT. The technology underpinning DVTect™ is based on an analysis of oscillometric waveforms generated in the calf muscle. DVTect™ comprises an accelerometer attached to the calf, with the waveforms sent to a linked device for analysis by proprietary software.
Dr David Sly, Senior Lecturer in Clinical Technologies and Neuroscience at Swinburne University, noted: “The Swinburne team is excited to be working with Kynetyka and the MDPP on the novel DVTect™ technology. Along with Dr. Adin Tan and Stuart Favilla from Swinburnes’ Centre for Design Innovation, our aim is to optimise the data capture system, including selection and integration of appropriate sensors, and to update the data analysis software. The outcome will be a fully-functional user-friendly prototype ready for proof-of-concept testing in the clinic.”
Professor Sally McArthur, Victorian Regional Director for Medical Device Partnering Program added: “The DVTect™ project is a great example of Victoria’s MDPP in action. Supported by LaunchVic, the MDPP assists energetic start-ups like Kynetyka to get their medical device along the path to market. Each project kicks off with a MDPP-facilitated workshop involving key stakeholders. At the DVTect™ Workshop, doctors who diagnose and manage the treatment of DVT reinforced the need for a device for screening of DVTs in patients. MDPP looks forward to helping Kynetyka to meet that need.”
The MDPP DVTect™ development project is expected to run until mid-2021.
For further information, contact:
Kynetyka Technologies Pty Ltd
Craig Newton, Director
Phone: +61 (0) 434 674 256
Medical Device Partnering Program (Victoria)
Zoe Kristall, Innovations Manager
Phone: +61 (0) 416 767 118
Dr David Sly, Senior Lecturer in Clinical Technologies and Neuroscience
Phone: +61 3 9214-4370
Kynetyka Technologies Pty Ltd
Kynetyka Technologies Pty Ltd (Kynetyka) is an Australian medical device company, incorporated in September 2017 and headquartered in Melbourne. The company is focused on developing their proprietary and unique DVTect™ technology through to commercialisation. The DVTect™ technology enables screening for deep vein thrombosis in at-risk patients.
Kynetyka’s executive team has collectively over 80 years’ experience in the medical/pharmaceutical and technology development sectors both domestically and internationally; their detailed product development knowledge is enabling expeditious development of the device to market. Their experience in engineering, and quality and regulatory compliance ensures the device will be studied appropriately in the clinic and developed to meet national and international regulatory standards. Previous organisations that they have worked with include CSL Limited and CSL Behring (Australia, Switzerland, USA), CSIRO, Serono (UK), Invion Limited, Epworth HealthCare and La Trobe University.
Deep Vein Thrombosis (DVT)
DVT is a significant complication in all surgical and medical wards, as well as in other aspects of community life. It can lead to pulmonary embolism (clots in the lungs) and possible death. There are also dangers of continuing morbidity in the legs and the lungs from the presence of venous thrombo-embolism. At the present time, there is no recognised clinical assessment that has an accuracy greater than 60%; many patients with DVT have no overt clinical findings. Where there are suspicious findings, the specific investigations for confirmation usually involve Doppler ultrasound, which is expensive and requires significant capital equipment and expertise.